PT-141 Nasal Spray
PT-141 was first developed as a nasal spray — the injectable you may have read about came later.
Bremelanotide, a melanocortin agonist that acts on central arousal pathways rather than blood flow.
1 bottle
10ml · 10mg
R 520
VAT inclusive · Shipped nationwide from Johannesburg · Research use only
What’s in each spray
The spray arrives already in solution, so the arithmetic is done for you. Figures assume a standard 0.1 mL metered pump.
Per bottle
10mg
in 10ml
Per mL
1mg
concentration
Per spray
100mcg
at 0.1 mL a spray
Sprays
~100
per bottle, before priming
Why PT-141 as a nasal spray
Bremelanotide (PT-141) began its clinical life as an intranasal product. Palatin Technologies ran its early human trials with a nasal spray, in men with erectile dysfunction and in women with sexual arousal disorder, and it absorbed quickly: in a 2004 trial the peak blood level came about 30 minutes after dosing.
The company later switched to an under-the-skin injection. That is the form the FDA approved in 2019 as Vyleesi, for hypoactive sexual desire disorder in premenopausal women, after two phase 3 trials. This spray returns the compound to its original route.
About PT-141
PT-141 (bremelanotide) is a melanocortin receptor agonist — it acts on MC3R/MC4R pathways in the brain rather than on vascular tissue the way traditional ED medications do. It is notable in this range for having an approved pharmaceutical form (Vyleesi, an injectable) for hypoactive sexual desire disorder in women, and it has separately been studied for erectile dysfunction in men.
That central mechanism — nervous system arousal pathways rather than local blood flow — is what sets PT-141 apart in the research literature. Side effects reported in that literature include nausea, flushing and transient blood pressure changes.
Read the full PT-141 compound profileWhat the research covers
Published findings, not promised outcomes. Studies are listed under Sources below.
Early intranasal trials
Diamond et al. (2004) gave intranasal PT-141 to healthy men and to men with erectile dysfunction, and found significant erectile responses at higher doses, with a first response after about 30 minutes.
A central mechanism
PT-141 acts on melanocortin receptors in the brain rather than on blood flow, which is how it differs from sildenafil-type drugs.
The approved form
Kingsberg et al. (2019) reported the two RECONNECT phase 3 trials of the injectable in women, the evidence behind its FDA approval.
Where the evidence is thin
Flushing and nausea were the most common side effects in the intranasal trials, and blood pressure changes have been reported for the compound. The approved product is the injection, not a nasal spray, so the intranasal evidence comes from the earlier development trials.
Spray, vial or pen
PT-141 comes in all three formats. The compound is the same; what changes is the preparation and how it goes in.
Nasal spray
This pageR 520
10ml · 10mg
- Preparation
- Ready to use
- Delivery
- Intranasal, no needles
Using a nasal spray properly
- 1
Prime the pump
Before the first use, pump into the air until a fine, even mist comes out. Those first few sprays are not counted in the bottle total.
- 2
Clear your nose
Blow your nose gently first. A congested nose absorbs poorly and more of the spray runs straight out.
- 3
Aim away from the middle
Tilt your head slightly forward and point the nozzle toward the outer wall of the nostril, not the septum.
- 4
Breathe in gently
Press once while breathing in softly through the nose. A hard sniff pulls the spray down the throat instead of leaving it in the nose.
- 5
Alternate nostrils
Between sprays, alternate nostrils. That spreads the dose over more of the nasal lining.
Storage
Keep the bottle upright with the cap on, and in the fridge once opened. The amber glass protects the solution from light, but not from heat: don’t leave it in a parked car or a sunny window, especially in a South African summer. Don’t freeze it, and don’t share a nozzle between people.
Questions about the PT-141 spray
Sources
- Diamond LE et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141. Int J Impot Res. 2004.
- Diamond LE et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141). J Sex Med. 2006.
- Kingsberg SA et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019.
Order PT-141 Nasal Spray in South Africa
Add it to your order slip and send it when you’re ready. We’ll confirm stock, pricing and delivery on WhatsApp before you pay a cent.
For Research Use Only — not for human consumption.